Agilent Technologies - Utilizing Fast HPLC Screening Methods for the Detection of Steroids
As the importance of steroids in the regulation of bioprocesses has increased so has the demand for fast screening methods for their detection. HPLC is a highly regarded analytical technique for pharmaceutical applications due to its unrivalled analytical validation characteristics; including accuracy, precision, limit of detection, specificity, linearity and range, and ruggedness.
The high throughput demands of quantitative steroid analysis require faster run times and as a result there has been a focus on the development of fast HPLC screening methods to detect steroids such as hydrocortisone, testosterone and progesterone. Recent developments in HPLC column technology, such as sub-2 μm totally porous and sub-3 μm superficially porous columns, have offered improvements in separation speed and performance through reduced analysis times and increased separation efficiency. It is these improvements in column technology which mean that fast HPLC screening for the detection of steroids can be achieved.
Selectivity is the most powerful tool to optimize separations in HPLC and can be manipulated to improve separations. As a result, the analysis of steroids can be dramatically improved by choosing the optimal HPLC column for the separation. Selectivity can be increased by changing the mobile phase composition, column temperature and the composition of stationary phase; for example, the short column length and high efficiency of Poroshell 120 HPLC columns provide fast HPLC analysis times and rapid equilibration leading to fast investigations of selectivity.
A key feature of Poroshell 120 columns is their superficially porous microparticulate column packing. Poroshell 120 particles have a 1.7 μm solid silica core with a 0.5 μm porous outer layer. This unique configuration delivers all the performance advantages of sub-2 μm particles with the backpressure of a sub-3 μm particle. With Poroshell 120 columns, it is possible to achieve 80–90% or more of the efficiency expected from a sub-2 μm Fast LC/UHPLC column — but at HPLC pressures (below 400 bar). This ability to perform fast separations at low pressures can dramatically enhance productivity by allowing more samples to be run in less time — even using existing HPLC systems. This allows laboratories to generate better chromatographic results quicker so they can increase their throughput of samples.
To read the full story and discover how you can achieve fast HPLC screening methods click here.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance